Literature DB >> 7677997

Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives. Potency, binding characteristics, and effect of template sequence.

S S Carroll1, D B Olsen, C D Bennett, L Gotlib, D J Graham, J H Condra, A M Stern, J A Shafer, L C Kuo.   

Abstract

The inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by pyridinone compounds has been investigated using as templates synthetic RNA with sequences based on the HIV-1 genome sequence. In reactions catalyzed by the enzyme that incorporated more than one nucleotide per primer, inhibition by a representative pyridinone inhibitor, 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)one (L-696,229), was noncompetitive against deoxynucleotide triphosphate. For reactions that incorporated one deoxynucleotide per primer, IC50 values ranged from 20 to 200 nM, depending on the position of incorporation of the incoming deoxynucleotide base on the template. Inhibition of synthesis on a set of four templates differing only at the template base complementary to the incoming nucleotide had similar IC50 values. These results demonstrate that inhibitory potency is dependent on the primary structure of the template and that inhibitory potency is largely independent of the identity of the incoming nucleotide base. The inhibition of HIV-1 reverse transcription by L-696,229 also displayed slow-binding characteristics. The slow-binding aspect was exploited to gauge the interaction between inhibitor and enzyme. By titrating the reduction in the extent of the burst of synthesis observed in a reaction incorporating dideoxythymidine monophosphate into poly(rA)-oligo(dT)18, the apparent equilibrium constant for dissociation of the reverse transcriptase-L-696,229 complex was estimated to be 400 nM.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7677997

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.

Authors:  G Maga; U Hübscher; M Pregnolato; D Ubiali; G Gosselin; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.

Authors:  Dongyuan Piao; Aravind Basavapathruni; Pinar Iyidogan; Guangxiu Dai; Wolfgang Hinz; Adrian S Ray; Eisuke Murakami; Joy Y Feng; Fei You; Ginger E Dutschman; David J Austin; Kathlyn A Parker; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2012-12-20       Impact factor: 2.823

3.  L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S D Young; S F Britcher; L O Tran; L S Payne; W C Lumma; T A Lyle; J R Huff; P S Anderson; D B Olsen; S S Carroll
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

4.  Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor.

Authors:  D B Olsen; S S Carroll; J C Culberson; J A Shafer; L C Kuo
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

Review 5.  Potential anti-HIV agents from marine resources: an overview.

Authors:  Thanh-Sang Vo; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-11-29       Impact factor: 5.118

6.  Molecular characterization of HIV-1 genome in fission yeast Schizosaccharomyces pombe.

Authors:  Joseph Nkeze; Lin Li; Zsigmond Benko; Ge Li; Richard Y Zhao
Journal:  Cell Biosci       Date:  2015-08-25       Impact factor: 7.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.